
ICU Medical (ICUI) Stock Forecast & Price Target
ICU Medical (ICUI) Analyst Ratings
Bulls say
ICU Medical's positive outlook is supported by its status as a leading player in the infusion therapy market, bolstered by recent acquisitions that enhance its operational footprint and product offerings. The company's financial profile is poised for improvement, with pro forma estimates suggesting revenue growth exceeding 100 basis points, an increase in gross margin by nearly 50 basis points, and an EBITDA margin projected to surpass 20%. Additionally, ICU Medical's positioning at the forefront of a new product and pump replacement cycle indicates potential for increased investor interest and a stronger valuation multiple in the medtech sector.
Bears say
ICU Medical's financial outlook is challenged by a significant burden from its Vital Care segment, which operates at gross margins 300-400 basis points lower than the company's other segments, Consumables and Infusion Systems. The anticipated removal of approximately $35 million in annual EBITDA contribution could help lower the company's leverage, potentially bringing it below the 2x target; however, this would merely address a portion of the underlying operational inefficiencies. Additionally, the company's reliance on domestic sales, comprising over 60% of total revenue, may limit growth opportunities in a competitive global market, further exacerbating concerns regarding future profitability and market positioning.
This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.
ICU Medical (ICUI) Analyst Forecast & Price Prediction
Start investing in ICU Medical (ICUI)
Order type
Buy in
Order amount
Est. shares
0 shares